# SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

> **NCT01053962** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Chronic Idiopathic Constipation

## Interventions

- **DRUG:** SP-304 0.3 mg
- **DRUG:** SP-304 1.0 mg
- **DRUG:** SP-304 3.0 mg
- **DRUG:** SP-304 9.0 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01053962
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01053962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01053962, "SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01053962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*